Standard BioTools and Treeline Biosciences have agreed to merge in an all-stock deal expected to close in the second half of 2026, creating a combined company named Treeline Biosciences. The new entity will focus on developing precision medicines, including small molecule inhibitors and targeted therapies, with a strong oncology pipeline featuring multiple clinical programs starting data readouts in 2027. The merger brings over $900 million in cash, funding operations through 2029, and is led by Treeline CEO Josh Bilenker, who has a proven track record in drug development. Standard BioTools will explore strategic options for its Mass Cytometry and Microfluidics businesses separately.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
